TCR2 Therapeutics Inc. Common Stock
TCRR
TCRR was delisted on the 31st of May, 2023.
50 hedge funds and large institutions have $111M invested in TCR2 Therapeutics Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 13 reducing their positions, and 4 closing their positions.
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
38% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 13
11% more funds holding
Funds holding: 45 → 50 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
45% less capital invested
Capital invested by funds: $203M → $111M (-$91.9M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $109K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$1.14M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$1M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$964K |
| 4 |
Renaissance Technologies
New York
|
+$628K |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$375K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.42M |
| 2 |
FAM
Formidable Asset Management
Cincinnati,
Ohio
|
-$540K |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$390K |
| 4 |
Squarepoint
New York
|
-$199K |
| 5 |
Morgan Stanley
New York
|
-$193K |
TCRR Hedge Fund Activity: Q1 2020 in Review
50 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q1 2020, worth a combined $111M — down 45% from $203M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new TCRR positions and 4 closed out — a net gain of 5 holders — while 18 added to existing stakes and 13 trimmed.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $1.14M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $3.42M sold.
- 50 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q1 2020, up from 45 in Q4 2019.
- Funds reported $111M of TCR2 Therapeutics Inc. Common Stock stock for Q1 2020, down 45% quarter-over-quarter.
- 9 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q1 2020 and 4 closed out, a net change of +5 holders.
- The largest TCR2 Therapeutics Inc. Common Stock buyer in Q1 2020 was ArrowMark Colorado Holdings, an estimated $1.14M added.
- The largest TCR2 Therapeutics Inc. Common Stock seller in Q1 2020 was EcoR1 Capital, an estimated $3.42M sold.
Based on aggregated 13F filings for Q1 2020.